1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea is a **complex organic compound** with a rather complicated structure. It's important to break down its name and structure to understand its potential significance:
**Structure:**
* **Thiourea:** The core of the molecule is thiourea, which contains a sulfur atom double-bonded to a carbon atom, connected to two nitrogen atoms.
* **Ethyl group:** Attached to one of the nitrogen atoms is an ethyl group (-CH2CH3).
* **Phenylmethyl group:** The other nitrogen is linked to a more complex structure: a phenylmethyl group (-CH2-C6H5), which is a benzyl group.
* **Sulfanylidenemethyl group:** This group (-CH=S-) links the benzyl group to the thiourea core.
**Importance in Research:**
While the specific compound you mentioned may not be well-documented, similar thiourea derivatives are often explored in research for various reasons:
* **Biological Activity:** Thioureas are known for their diverse biological activities, including potential as:
* **Antimicrobial agents:** They can inhibit the growth of bacteria and fungi.
* **Anti-cancer agents:** Some thiourea derivatives can inhibit tumor cell growth.
* **Anti-inflammatory agents:** They may reduce inflammation in the body.
* **Material Science:** Certain thioureas are employed in the synthesis of polymers and other materials. Their ability to form strong bonds makes them useful for various applications.
* **Analytical Chemistry:** Thioureas are sometimes used as reagents in analytical chemistry, due to their ability to form complexes with metal ions.
**To understand the specific importance of 1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea, further information is needed.**
**Possible Research Avenues:**
* **Synthesis and Characterization:** Determining the most effective methods for synthesizing the compound and characterizing its properties (structure, melting point, solubility, etc.).
* **Biological Activity:** Evaluating the compound's effects on various biological systems (bacterial growth, cancer cell lines, inflammatory processes).
* **Material Science Applications:** Investigating potential uses in materials science, such as polymers, coatings, or other materials.
**Finding More Information:**
To learn more about this specific compound, you would need to search for research publications that mention its name or chemical structure. You can use databases like PubChem, SciFinder, or Google Scholar for this purpose.
ID Source | ID |
---|---|
PubMed CID | 1825238 |
CHEMBL ID | 1408451 |
CHEBI ID | 107326 |
Synonym |
---|
HMS2583D21 |
MLS-0232971.0002 , |
MLS-0232971.0001 |
n~1~-benzyl-n~2~-ethyl-1,2-hydrazinedicarbothioamide |
MLS000705903 |
smr000225838 |
n-benzyl-n'-ethylhydrazine-1,2-dicarbothioamide |
STK079642 |
CHEBI:107326 |
AKOS000352261 |
1-benzyl-3-(ethylcarbamothioylamino)thiourea |
bdbm43805 |
cid_1825238 |
1-ethyl-3-[[[(phenylmethyl)amino]-sulfanylidenemethyl]amino]thiourea |
1-benzyl-3-(ethylthiocarbamoylamino)thiourea |
1-ethyl-3-[(phenylmethyl)carbamothioylamino]thiourea |
HNVKQXJBINMTGG-UHFFFAOYSA-N |
benzene, 1-[[[[2-[(ethylamino)carbonothioyl]hydrazino]carbonothioyl]amino]methyl]- |
CHEMBL1408451 |
Q27185555 |
1-[(benzylcarbamothioyl)amino]-3-ethylthiourea |
SR-01000534920-1 |
sr-01000534920 |
Class | Description |
---|---|
benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0032 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 89.1251 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 1.2589 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 56.2341 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.6310 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 10.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 3.5210 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 35.4813 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 21.2804 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 32.6427 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 1.2589 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.1100 | 11.3862 | 67.2000 | AID1512 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | EC50 (µMol) | 15.5933 | 0.2270 | 25.0904 | 86.8000 | AID1001; AID1450; AID1659 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |